Citation Impact
Citing Papers
TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells
2014
De novo design of modular and tunable protein biosensors
2021 StandoutNatureNobel
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Myeloid Growth Factors
2011
Gender medicine and oncology: report and consensus of an ESMO workshop
2019
Metal–organic framework composites
2014 Standout
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
2009
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
2007
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
2007
Kinetics of Neutrophils in Mice Exposed to Radiation and/or Granulocyte Colony-Stimulating Factor Treatment
2013
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Rapid translocation of nanoparticles from the lung airspaces to the body
2010 StandoutNobel
Flexible metal–organic frameworks
2014 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
2008
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients
2003
Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma
2009
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Broad-Spectrum Antibiotic or G-CSF as Potential Countermeasures for Impaired Control of Bacterial Infection Associated with an SPE Exposure during Spaceflight
2015 StandoutNobel
Graves' Ophthalmopathy
2010 Standout
Nanomedicine
2006
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
2008
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
2007
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Metal–Organic Frameworks from Edible Natural Products
2010 StandoutNobel
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Hindlimb Suspension and SPE-Like Radiation Impairs Clearance of Bacterial Infections
2014 StandoutNobel
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia
2003
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
2003
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
2007
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
2006
Mixing of immiscible polymers using nanoporous coordination templates
2015 StandoutNobel
Combining UV Lithography and an Imprinting Technique for Patterning Metal‐Organic Frameworks
2013 StandoutNobel
The development of molecule-based porous material families and their future prospects
2022 StandoutNobel
Immunosuppressive Drugs for Kidney Transplantation
2004 Standout
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
2009
New Drugs for Rheumatoid Arthritis
2004
Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
2005 Standout
Cation-Triggered Drug Release from a Porous Zinc−Adeninate Metal−Organic Framework
2009
Symbiosis of zeolite-like metal–organic frameworks (rho-ZMOF) and hydrogels: Composites for controlled drug release
2011
Metal–Organic Frameworks as A Tunable Platform for Designing Functional Molecular Materials
2013 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Structuring of metal–organic frameworks at the mesoscopic/macroscopic scale
2014 StandoutNobel
Highly Photoconducting π-Stacked Polymer Accommodated in Coordination Nanochannels
2012 StandoutNobel
Aromatizing Olefin Metathesis by Ligand Isolation inside a Metal– Organic Framework
2013 StandoutNobel
Hybridization of MOFs and polymers
2017 StandoutNobel
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
2006
Zr-based metal–organic frameworks: design, synthesis, structure, and applications
2016 Standout
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Carbon capture and conversion using metal–organic frameworks and MOF-based materials
2019 StandoutNobel
Methane storage in metal–organic frameworks
2014 Standout
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
2002
Tuning the structure and function of metal–organic frameworks via linker design
2014 Standout
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Luminescent metal–organic frameworks for chemical sensing and explosive detection
2014 Standout
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Functional Hybrid Porous Coordination Polymers
2013 StandoutNobel
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
2011 Standout
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
2005
Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma
2003
Ionizing Radiation Selectively Reduces Skin Regulatory T Cells and Alters Immune Function
2014 StandoutNobel
A Metal–Organic Framework-Based Material for Electrochemical Sensing of Carbon Dioxide
2014 StandoutNobel
Metal–organic frameworks meet metal nanoparticles: synergistic effect for enhanced catalysis
2017 Standout
Metal–Organic Frameworks for Separations
2011 Standout
Metal–Organic Frameworks in Biomedicine
2011 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
2004
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution
2015
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Metal–Organic Frameworks and Self-Assembled Supramolecular Coordination Complexes: Comparing and Contrasting the Design, Synthesis, and Functionality of Metal–Organic Materials
2012 Standout
Dual-Color Bioluminescent Sensor Proteins for Therapeutic Drug Monitoring of Antitumor Antibodies
2018
Metal–Organic Frameworks for Heterogeneous Basic Catalysis
2017 Standout
Works of Bingbing Yang being referenced
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
2012
Fixed-dose Pegfilgrastim is Safe and Allows Neutrophil Recovery in Patients with Non-Hodgkin's Lymphoma
2003
Population Pharmacokinetic Analysis of Panitumumab in Patients With Advanced Solid Tumors
2009
Pharmacokinetics of anakinra in subjects with different levels of renal function
2003
Pharmacokinetic and Pharmacodynamic Comparisons of Twice Daily and Four Times Daily Formulations of Procainamide in Patients with Frequent Ventricular Premature Depolarization
1996
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
2002
Serum Pegfilgrastim Concentrations During Recovery of Absolute Neutrophil Count in Patients with Cancer Receiving Pegfilgrastim After Chemotherapy
2007
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
1999
Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy
2000
Pharmacodynamics and Pharmacokinetic‐Pharmacodynamic Relationships of Atorvastatin, an HMG‐CoA Reductase Inhibitor
2000